- Previous Close
27.44 - Open
28.15 - Bid 28.26 x --
- Ask 28.30 x --
- Day's Range
27.24 - 28.56 - 52 Week Range
18.80 - 38.37 - Volume
1,720,300 - Avg. Volume
2,131,672 - Market Cap (intraday)
3.691B - Beta (5Y Monthly) -0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-1.02 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 1, 2020
- 1y Target Est
--
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products includes Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; indometacin and furazolidone suppositories for internal and external hemorrhoids, anal swelling, fistula, and other anorectal diseases; tinidazole suppositories for trichomonas vaginitis and bacterial vaginosis; nimodipine sustained release tablets for ischemic cerebrovascular disease, migraine, and cerebral vasospasm; trimetazidine dihydrochloride tablets for treatment of stable angina; and azithromycin granules for treatment of acute pharyngitis, tonsillitis, and bronchitis. The company also provides measles and rubella virus nucleic acid detection kit; isolation and identification tube and kit for mycoplasma; and bacterial vaginosis (BV) rapid test kit, as well as diagnostic kit for novel coronavirus N-Protein. In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kit for a Thalassemia. Further, the company provides Lopinavir and Ritonavir APIs; and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
www.hiteck.com.cn1,520
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 300683.SZ
View MorePerformance Overview: 300683.SZ
Trailing total returns as of 11/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300683.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300683.SZ
View MoreValuation Measures
Market Cap
3.59B
Enterprise Value
2.77B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.02
Price/Book (mrq)
1.47
Enterprise Value/Revenue
4.50
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-21.82%
Return on Assets (ttm)
-3.45%
Return on Equity (ttm)
-5.58%
Revenue (ttm)
614.85M
Net Income Avi to Common (ttm)
-134.13M
Diluted EPS (ttm)
-1.02
Balance Sheet and Cash Flow
Total Cash (mrq)
877.57M
Total Debt/Equity (mrq)
2.13%
Levered Free Cash Flow (ttm)
-59.21M